IEX

IDEX Corp. Q1 2003 Financial Summary

Business Context and Reporting Period

This Form 10-Q covers the three-month period ended March 31, 2003. IDEX Corporation manufactures and sells pump products, dispensing equipment, and other engineered products to a diverse global customer base. The company operates as a short-cycle business with limited visibility into future conditions, relying heavily on current order rates.

Key Financial Metrics

Material Changes vs. Prior Period

• Sales Growth: Net sales increased 12% year-over-year. This was driven by a 4% contribution from acquisitions (Halox, Rheodyne, Wrightech), a 5% boost from favorable foreign currency translation, and a 3% increase in base business shipments.
• Profitability: Net income rose 10% to $12.7 million. However, operating margins declined from 12.9% to 12.0% due to an unfavorable sales mix (shift away from higher-margin Pump Products) and increased Selling, General, and Administrative (SG&A) expenses.
• SG&A Expenses: Increased by $8.0 million (to $50.9 million). Approximately 25% of this increase was due to costs associated with the sale of a non-material product line, resolution of patent infringement litigation, and adjustments for a foreign subsidiary. The remainder reflected acquisition impacts and reinvestment in growth.
• Interest Expense: Decreased significantly from $4.7 million to $3.7 million, attributed to lower debt levels and a favorable interest rate environment.
• Cash Flow: Operating cash flow decreased 29% to $16.9 million, primarily due to working capital changes (increased receivables and inventory) required to support higher sales volume.

Outlook, Risks, and Management Commentary

• Outlook: Management is encouraged by the second consecutive quarter of year-over-year sales growth in base businesses. They believe the company is well-positioned for earnings improvements as the economy strengthens, citing lower cost structures and operational excellence initiatives (Kaizen, Lean Manufacturing, Six Sigma).
• Acquisitions: The company continues to pursue acquisitions to drive long-term profitable growth. An $8.0 million deferred payment for the Rheodyne acquisition was made in February 2003.
• Liquidity: Working capital stands at $128.8 million with a current ratio of 2.3 to 1. The company has a $300 million revolving credit facility with $50 million currently borrowed. Standard & Poor's upgraded the corporate credit rating to BBB in March 2003.
• Risks: Key risks include economic conditions in the U.S. and abroad, the impact of the September 11 attacks and the war in Iraq, foreign currency fluctuations, and the ability to integrate acquired businesses. The company maintains low order backlogs (slightly over one month's sales), making performance sensitive to current order rates.
• Contingencies: The company is involved in asbestos-related litigation; however, no provision has been made in financial statements as insurance is expected to cover costs, and management does not believe the claims will have a material adverse effect.

Investor Verification Checklist

• Verify the sustainability of the 3% base business sales growth excluding acquisitions and currency effects.
• Monitor the trajectory of SG&A expenses to ensure the one-time litigation and product line sale costs do not indicate a structural increase in overhead.
• Review the impact of foreign currency translation on future quarters given that 45% of sales are international.
• Assess the company's ability to maintain operating margins above the Value Line Corporate Index average as sales volumes fluctuate.
• Confirm the status of the $238.2 million debt load relative to the credit facility covenant (debt limited to 3x operating cash flow).